Menu
Close
Marketing Authorisation has been granted in the EU for PAXLOVID® for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Medicinal product subject to medical prescription.
On the 24 of January 2023 a new shelf-life for PAXLOVID® has been approved in the European Union (EU).
To find out more information about this update including the expiry date, click on the button below to view the Dear Healthcare professional (DHCP) Letter.
PAXLOVID® Summary of Product Characteristics (SmPC)
View the full Summary of Product Characteristics, which includes dosing, clinical data, and safety information.
PAXLOVID® Package Leaflet: Information for the Patient
View the Package Leaflet, which contains important information for the patient about how to take PAXLOVID and what to expect from treatment.
Ensuring the Authenticity of PAXLOVID®
Authentic PAXLOVID® from Pfizer will include the Pfizer name on the outer carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. Nirmatrelvir tablets are pink, oval-shaped and debossed with ‘PFE’ on one side and ‘3CL’ on the other side.Ritonavir tablets are white to off white, capsule shaped, and debossed with ‘H’ on one side and ‘R9’ on the other side.
The outer carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.
The flaps at each end of the carton are glued as a tamper evident feature of the packaging.
If you suspect the PAXLOVID® you have received may be counterfeit, please report it to your local representative in Latvia via +37167035775.
This site is intended only for healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Pfizer Luxembourg SARL Latvia Branch. © 2023 Pfizer Inc. All rights reserved. PP-C1D-LVA-0012
Šī informācija nav paredzēta pacientiem un citiem iedzīvotājiem, kas nav veselības aprūpes speciālisti.
Es apstiprinu, ka esmu veselības aprūpes speciālists un Latvijas rezidents.
Ja jūs izvēlieties "Nē", Jūs tiksiet novirzīts uz covid19oralrx.com, kur Jums būs iespēja piekļūt atsauces informācijai par PAXLOVID® (nirmatrelvirum; ritonavirum). Nirmatrelvirum [iepriekš PF-07321332].